CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 221 enrolled
Drug / intervention
mPDiadevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04334902
NCT04334902N/ACompleted
CompareCT.gov

An Open Label, Multicenter, Retrospective, Pivotal Trial to Evaluate the Efficacy of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images

Heuron Inc.·observational·Posted Apr 6, 2020·Updated Oct 29, 2025

In Brief

An observational study evaluating mPDia for Diagnoses Disease. Completed, enrolled 221 participants across 10 sites.

Detailed Summary

mPDia is a software that has been pre-learned based on a neurodegenerative parkinsonism diagnosis model using Nigrosome 1 MRI images, and clinical decision support system for diagnosing neurodegenerative parkinsonism by automatically analyzing Nigrosome 1 MRI images by assisting the medical team. The specific aims of this study are to evaluate efficacy of mPDia for neurodegenerative Parkinsonism compared to the sensitivity and specificity levels of 18F FP-CIT PET/CT which is currently used to diagnose neurodegenerative parkinsonism.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiagnoses Disease
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 6, 2020
Enrollment StartMar 13, 2020
Primary CompletionJun 24, 2020
Study CompletionOct 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.2 years ago

Interventions

mPDiadevice

Clinical decision support system for diagnosing neurodegenerative parkinsonism